Loading...
Market
What will be the market uptake of Leqembi in the UK by August 22, 2025?
2
Resolution / Starting Odds
High uptake (over 10,000 patients) • 25%
Moderate uptake (5,000-10,000 patients) • 25%
Low uptake (1,000-5,000 patients) • 25%
Very low uptake (under 1,000 patients) • 25%
Market research reports, sales data from Eisai and Biogen
Story
UK Approves Costly Alzheimer's Drug Leqembi, Not Available on NHS
Aug 22, 2024, 09:19 AM
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Leqembi, also known as Lecanemab, a drug developed by Eisai and Biogen, which has been shown to slow the progression of Alzheimer's disease. Approved on Thursday, the drug is licensed for adult patients in the early stages of Alzheimer's. Despite its approval, Leqembi will not be available on the National Health Service (NHS) due to its high cost and limited benefits. The National Institute for Health and Care Excellence (NICE) has stated that the benefits of Lecanemab, which slows disease progression by an average of 4-6 months, do not justify the significant expense required for treatment and monitoring. This decision has sparked disappointment among patients and healthcare professionals, as the drug represents a significant advancement in Alzheimer's treatment.
View original story
Similar markets
More than $500 million • 25%
$300 million to $500 million • 25%
$100 million to $300 million • 25%
Less than $100 million • 25%
High (>20% of target market) • 25%
Moderate (10%-20% of target market) • 25%
Low (1%-10% of target market) • 25%
Negligible (<1% of target market) • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,000 to 30,000 • 25%
More than 30,000 • 25%
